We are live on ! Find out more
EVOK

Evoke Pharma
EVOK

Delisted

EVOK was delisted on the 16th of December, 2025.

Back to rankings

20 hedge funds and large institutions have $7.92M invested in Evoke Pharma in 2018 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

67% more capital invested

Capital invested by funds: $4.76M → $7.92M (+$3.17M)

4.12% more ownership

Funds ownership: 14.76% → 18.89% (+4.1%)

0% more funds holding

Funds holding: 20 → 20 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

Holders
20
Holders Change
–
Holders Change %
0%
% of All Funds
0.46%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
4
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
+$2.65M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$79.8K
3
TSS
Two Sigma Securities
New York
+$49.1K
4
VF
Virtu Financial
New York
+$40.9K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$33.4K

Top Sellers

Rank Fund Capital Flow
1
Deutsche Bank
Deutsche Bank
Germany
-$416K
2
JGC
J. Goldman & Co
New York
-$52K
3
Wells Fargo
Wells Fargo
California
-$11K
4
UBS Group
UBS Group
Switzerland
-$6.37K

EVOK Hedge Fund Activity: Q2 2018 in Review

20 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q2 2018, worth a combined $7.92M — up 67% from $4.76M a quarter earlier.

Fund positioning in EVOK was balanced in Q2 2018: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 1 trimmed.

The largest buyer was Sphera Funds Management, adding an estimated $2.65M. The largest seller was Deutsche Bank, exiting entirely with an estimated $416K sold.

  • 20 institutional investors held Evoke Pharma (EVOK) as of Q2 2018, unchanged from Q1 2018.
  • Funds reported $7.92M of Evoke Pharma stock for Q2 2018, up 67% quarter-over-quarter.
  • 3 funds opened new Evoke Pharma positions in Q2 2018 and 3 closed out, a net change of 0 holders.
  • The largest Evoke Pharma buyer in Q2 2018 was Sphera Funds Management, an estimated $2.65M added.
  • The largest Evoke Pharma seller in Q2 2018 was Deutsche Bank, an estimated $416K sold.

Based on aggregated 13F filings for Q2 2018.